Dick’s Sporting Goods Reports Strong Results And Reaffirms Guidance
Dick’s Sporting Goods (DKS) has reported strong financial results for this year’s first quarter and reaffirmed its full-year guidance, which includes the expected impact from import tariffs. The sporting goods retailer announced earnings per share (EPS) of $3.37 U.S., which topped the $3.20 U.S. anticipated by analysts. Revenue in the period totaled a record $3.17 billion U.S., which surpassed the $3.13 billion U.S. forecast on Wall Street. Sales were up 5.2% from a year earlier. Looking ahead, management reaffirmed their outlook for the entire fiscal year, saying they still expect earnings of $13.80 U.S. to $14.40 U.S. per share. That outlook remains in line with the $14.29 U.S. that analysts had expected from the company. Full-year revenue is forecast to be between $13.60 billion U.S. and $13.90 billion U.S., which is also in line with Wall Street expectations of $13.90 billion U.S.Dick’s latest results were preannounced two weeks ago when it announced that it is acquiring longtime rival Foot Locker (FL) for $2.40 billion U.S. The purchase of Foot Locker will allow Dick’s Sporting Goods to expand into international markets outside the U.S. for the first time and grow its presence in the sneaker market.However, some analysts have expressed concerns that Dick’s is acquiring a business that’s been struggling for years and has poor financials. The Foot Locker purchase is expected to close in the second half of this year.Dick’s stock has declined 23% in 2025 to trade at $174.22 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


